MCID: ACT193
MIFTS: 59

Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22)

Categories: Rare diseases, Cancer diseases, Blood diseases, Bone diseases, Immune diseases

Aliases & Classifications for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils...

MalaCards integrated aliases for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22):

Name: Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22) 53 59
Acute Myelomonocytic Leukemia 53 59 29 73
Aml with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22) 53 59
Aml M4 53 59
Ammol 53 59
Aml with Inv(16)(p13.1q22) or T(16;16)(p13.1;q22) 53
Acute Myeloblastic Leukemia Type 4 53
Leukemia, Acute Myelomonocytic 13
Leukemia Myelomonocytic Acute 55
Cbfb-Myh11 53
Aml-M4 53

Characteristics:

Orphanet epidemiological data:

59
acute myelomonocytic leukemia
Inheritance: Not applicable; Age of onset: Adult;

Classifications:



External Ids:

ICD10 via Orphanet 34 C92.5
MESH via Orphanet 45 D015479
UMLS via Orphanet 74 C0023479
ICD10 33 C92.5
UMLS 73 C0023479

Summaries for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils...

NIH Rare Diseases : 53 Acute myelomonocytic leukemia (AMML) is a cancer that typically develops in the bone marrow and blood of older individuals.  AMML is one type of acute myeloid leukemia, a group of blood cancers that occur when the amount of white blood cells increases rapidly.  Symptoms of AMML often include fatigue (due to anemia) or easy bruising or bleeding (due to thrombocytopenia).  The cause of AMML is currently unknown.  Treatment typically consists of chemotherapy.

MalaCards based summary : Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22), also known as acute myelomonocytic leukemia, is related to leukemia and ring chromosome 21, and has symptoms including fatigue and fever. An important gene associated with Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22) is CBFB (Core-Binding Factor Subunit Beta), and among its related pathways/superpathways are PAK Pathway and PI3K-Akt signaling pathway. The drugs Lenograstim and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils...

Diseases related to Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22) via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 112)
# Related Disease Score Top Affiliating Genes
1 leukemia 30.5 ETV6 FLT3 KIT RUNX1
2 ring chromosome 21 30.3 ETV6 KMT2A
3 leukemia, acute monocytic 29.3 CREBBP KMT2A MPO
4 lymphoblastic leukemia 29.2 ETV6 FLT3 RUNX1
5 myeloid sarcoma 29.1 DNTT FLT3 KIT KMT2A MPO
6 aleukemic leukemia cutis 29.1 FLT3 MPO MYH11 RUNX1
7 chronic myelomonocytic leukemia 29.1 ETV6 FLT3 KIT RUNX1
8 acute promyelocytic leukemia 29.0 CSF1R FLT3 MPO RUNX1
9 leukemia, acute lymphoblastic 27.9 DNTT ETV6 FLT3 KMT2A RUNX1
10 myeloid leukemia 27.1 CBFB CREBBP ETV6 FLT3 KIT MYH11
11 leukemia, chronic myeloid 27.0 DNTT ETV6 FLT3 KIT KMT2A MPO
12 acute leukemia 25.6 CREBBP DNTT ETV6 FLT3 KIT KMT2A
13 myelodysplastic syndrome 24.6 CREBBP CSF1 CSF1R DNTT ETV6 FLT3
14 acute myeloblastic leukemia with maturation 10.6 FLT3 KIT
15 acute myeloid leukemia with minimal differentiation 10.6 FLT3 MPO
16 cytogenetically normal acute myeloid leukemia 10.5 FLT3 KMT2A
17 lymphoplasmacytic lymphoma 10.5 CBFB MYH11
18 mast-cell sarcoma 10.5 KIT MPO
19 chronic eosinophilic leukemia 10.5 FLT3 KIT
20 uterine inversion 10.4 CSF1R KIT
21 acute basophilic leukemia 10.3 ETV6 MPO
22 polymorphous low-grade adenocarcinoma 10.3 KIT MYH11
23 sarcoma 10.3
24 platelet disorder, familial, with associated myeloid malignancy 10.2 ETV6 RUNX1
25 congenital mesoblastic nephroma 10.2 ETV6 KIT
26 b-cell childhood acute lymphoblastic leukemia 10.2 ETV6 RUNX1
27 neonatal leukemia 10.1 CREBBP FLT3
28 tetrasomy 21 10.1 DNTT RUNX1
29 mn1 10.1 ETV6 FLT3 KMT2A
30 lymphoid leukemia 10.1 ETV6 FLT3 KMT2A
31 myeloma, multiple 10.1
32 acute myeloid leukemia with t(8;21)(q22;q22) translocation 10.1 FLT3 KIT RUNX1
33 8p11 myeloproliferative syndrome 10.0 FLT3 KIT RUNX1
34 lymphoma 10.0
35 dendritic cell tumor 10.0 DNTT MPO
36 mycosis fungoides 10.0
37 gingivitis 10.0
38 acute biphenotypic leukemia 9.9 DNTT KMT2A MPO
39 lymphoblastic lymphoma 9.9 DNTT KMT2A MPO
40 leukemia, chronic lymphocytic 2 9.9
41 leukemia, chronic lymphocytic 9.9
42 vasculitis 9.9
43 macroglobulinemia 9.9
44 leukemia, b-cell, chronic 9.9
45 pdgfrb-associated chronic eosinophilic leukemia 9.9
46 adenoid cystic carcinoma 9.8 CREBBP KIT MYH11
47 childhood leukemia 9.8 ETV6 KMT2A RUNX1
48 tenosynovial giant cell tumor 9.8 CSF1 CSF1R
49 multiple cranial nerve palsy 9.8 MPO RUNX1
50 esophageal cancer 9.7

Graphical network of the top 20 diseases related to Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22):



Diseases related to Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22)

Symptoms & Phenotypes for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils...

UMLS symptoms related to Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22):


fatigue, fever

GenomeRNAi Phenotypes related to Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22) according to GeneCards Suite gene sharing:

26 (show all 32)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.07 MPO
2 Increased shRNA abundance (Z-score > 2) GR00366-A-102 10.07 KIT DNTT FLT3
3 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.07 FLT3
4 Increased shRNA abundance (Z-score > 2) GR00366-A-116 10.07 FLT3
5 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.07 FLT3
6 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.07 FLT3
7 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.07 FLT3
8 Increased shRNA abundance (Z-score > 2) GR00366-A-123 10.07 DNTT FLT3
9 Increased shRNA abundance (Z-score > 2) GR00366-A-126 10.07 MPO
10 Increased shRNA abundance (Z-score > 2) GR00366-A-138 10.07 DNTT
11 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.07 DNTT
12 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.07 KIT
13 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.07 MPO DNTT KIT
14 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.07 DNTT
15 Increased shRNA abundance (Z-score > 2) GR00366-A-163 10.07 FLT3
16 Increased shRNA abundance (Z-score > 2) GR00366-A-170 10.07 KIT
17 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.07 MPO
18 Increased shRNA abundance (Z-score > 2) GR00366-A-182 10.07 DNTT
19 Increased shRNA abundance (Z-score > 2) GR00366-A-186 10.07 MPO
20 Increased shRNA abundance (Z-score > 2) GR00366-A-197 10.07 DNTT
21 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.07 FLT3
22 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.07 MPO
23 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.07 KIT
24 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.07 MPO
25 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.07 KIT
26 Increased shRNA abundance (Z-score > 2) GR00366-A-57 10.07 MPO
27 Increased shRNA abundance (Z-score > 2) GR00366-A-7 10.07 MPO
28 Increased shRNA abundance (Z-score > 2) GR00366-A-70 10.07 MPO FLT3
29 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.07 DNTT
30 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.07 KIT
31 Increased shRNA abundance (Z-score > 2) GR00366-A-9 10.07 KIT
32 Increased shRNA abundance (Z-score > 2) GR00366-A-99 10.07 KIT

MGI Mouse Phenotypes related to Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22):

46 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.29 MYH11 KMT2A RUNX1 MPO CSF1 CREBBP
2 cardiovascular system MP:0005385 10.28 MPO MYH11 KMT2A RUNX1 CSF1 CREBBP
3 cellular MP:0005384 10.27 MYH11 KMT2A RUNX1 CBFB CSF1 CREBBP
4 hematopoietic system MP:0005397 10.26 KMT2A RUNX1 MPO CSF1 CREBBP CSF1R
5 growth/size/body region MP:0005378 10.24 MYH11 KMT2A RUNX1 CBFB CSF1 CREBBP
6 immune system MP:0005387 10.24 KMT2A RUNX1 MPO CSF1 CREBBP CSF1R
7 endocrine/exocrine gland MP:0005379 10.15 RUNX1 CBFB CSF1 CREBBP FLT3 KIT
8 mortality/aging MP:0010768 10.14 MPO MYH11 KMT2A RUNX1 CBFB CSF1
9 integument MP:0010771 10.13 MYH11 KMT2A RUNX1 CSF1 CREBBP CSF1R
10 craniofacial MP:0005382 10.04 KMT2A CBFB CSF1 CREBBP CSF1R KIT
11 embryo MP:0005380 10.03 KMT2A RUNX1 CREBBP CBFB ETV6 KIT
12 limbs/digits/tail MP:0005371 9.93 KMT2A CBFB CSF1 CREBBP CSF1R KIT
13 liver/biliary system MP:0005370 9.91 KMT2A RUNX1 CBFB CSF1 CREBBP KIT
14 neoplasm MP:0002006 9.87 KMT2A RUNX1 CBFB CREBBP KIT ETV6
15 no phenotypic analysis MP:0003012 9.86 KMT2A RUNX1 CSF1 CBFB KIT ETV6
16 muscle MP:0005369 9.85 MPO MYH11 KMT2A CSF1 CREBBP KIT
17 normal MP:0002873 9.76 KMT2A RUNX1 CBFB CREBBP DNTT KIT
18 respiratory system MP:0005388 9.43 MYH11 RUNX1 CBFB CSF1 CREBBP KIT
19 skeleton MP:0005390 9.23 KMT2A RUNX1 CBFB CSF1 CREBBP FLT3

Drugs & Therapeutics for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils...

Drugs for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22) (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 217)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
3
Thiotepa Approved, Investigational Phase 4,Phase 2,Phase 1 52-24-4 5453
4 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
5 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
6 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Antilymphocyte Serum Phase 4,Phase 2
9
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
10
Amsacrine Approved, Investigational Phase 3 51264-14-3 2179
11
Mesna Approved, Investigational Phase 3 3375-50-6 598
12
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 147-94-4 6253
13
Clofarabine Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 123318-82-1 119182
14
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
15
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 55-98-1 2478
16
Idarubicin Approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58957-92-9 42890
17
Mitoxantrone Approved, Investigational Phase 3,Phase 2,Phase 1 65271-80-9 4212
18
Daunorubicin Approved Phase 3,Phase 2,Phase 1 20830-81-3 30323
19
Thioguanine Approved Phase 3,Phase 1 154-42-7 2723601
20
Aldesleukin Approved Phase 3,Phase 1,Phase 2 85898-30-2, 110942-02-4
21
alemtuzumab Approved, Investigational Phase 2, Phase 3,Phase 1 216503-57-0
22
Fludarabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 21679-14-1, 75607-67-9 30751
23
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
24
Hydroxyurea Approved Phase 3 127-07-1 3657
25
Methotrexate Approved Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
26
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 1 50-02-2 5743
27
Melphalan Approved Phase 2, Phase 3,Phase 3,Phase 1 148-82-3 4053 460612
28
Azacitidine Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 320-67-2 9444
29
Decitabine Approved, Investigational Phase 3,Phase 2,Phase 1 2353-33-5 451668
30
Carmustine Approved, Investigational Phase 3 154-93-8 2578
31
Arsenic trioxide Approved, Investigational Phase 2, Phase 3,Phase 1 1327-53-3 518740
32
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
33
Caspofungin Approved Phase 3 179463-17-3, 162808-62-0 468682 2826718
34
Cyproheptadine Approved Phase 3 129-03-3 2913
35
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
36
Tretinoin Approved, Investigational, Nutraceutical Phase 3,Phase 2,Phase 1 302-79-4 5538 444795
37
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 143 6006
38
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
39
tipifarnib Investigational Phase 3,Phase 2,Phase 1 192185-72-1 159324
40 Staurosporine Experimental Phase 3,Phase 1 62996-74-1
41
Butyric Acid Experimental, Investigational Phase 3 107-92-6 264
42 Interleukin-2 Phase 3,Phase 1,Phase 2
43 Analgesics Phase 3,Phase 2,Phase 1
44 Gemtuzumab Phase 2, Phase 3,Phase 3,Phase 1
45 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
46 Dermatologic Agents Phase 3,Phase 2,Phase 1
47 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1
48 Vaccines Phase 3,Phase 1
49 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
50 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 190)
# Name Status NCT ID Phase Drugs
1 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
2 Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia in Remission Unknown status NCT00454168 Phase 3
3 Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia Unknown status NCT00002549 Phase 3 busulfan;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mesna;mitoxantrone hydrochloride
4 Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia Unknown status NCT00006045 Phase 3 cytarabine;etoposide;mitoxantrone hydrochloride
5 Combination Chemotherapy, Interleukin-2, and Peripheral Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia Unknown status NCT00004128 Phase 3 busulfan;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide
6 Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Unknown status NCT00091234 Phase 2, Phase 3 gemtuzumab ozogamicin
7 Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia Unknown status NCT00002658 Phase 3 amsacrine;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin
8 Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission Completed NCT00093470 Phase 3 Tipifarnib
9 Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia Completed NCT00006363 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar;busulfan
10 Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT00372593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;etoposide;gemtuzumab ozogamicin;mitoxantrone hydrochloride
11 Combination Chemotherapy With or Without Filgrastim and/or Tretinoin in Treating Patients With Acute Myeloid Leukemia Completed NCT00005863 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;fludarabine phosphate;tretinoin
12 Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed NCT00369317 Phase 3 asparaginase;daunorubicin hydrochloride;cytarabine;thioguanine;etoposide
13 Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia Completed NCT00003190 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar
14 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome Completed NCT00002798 Phase 3 asparaginase;daunorubicin hydrochloride;fludarabine phosphate;therapeutic hydrocortisone;cytarabine;idarubicin;dexamethasone;thioguanine;etoposide;methotrexate;cyclophosphamide;busulfan
15 Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes Completed NCT00454480 Phase 2, Phase 3 arsenic trioxide;azacitidine;busulfan;clofarabine;cytarabine;daunorubicin hydrochloride;fludarabine phosphate;gemtuzumab ozogamicin;melphalan;tipifarnib
16 Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia Completed NCT00002719 Phase 3 amsacrine;carmustine;cytarabine;etoposide;idarubicin;mitoxantrone hydrochloride
17 Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00005823 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;hydroxyurea;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin;valspodar
18 Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed NCT00121303 Phase 3 cytarabine;daunorubicin hydrochloride;gemtuzumab ozogamicin
19 Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia Completed NCT00112554 Phase 3 cytarabine;laromustine
20 flt3L in Treating Patients With Acute Myeloid Leukemia Completed NCT00006223 Phase 3
21 Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome Completed NCT00003593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;methotrexate;therapeutic hydrocortisone;thioguanine
22 Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00002517 Phase 3 cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine
23 S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML Completed NCT00085709 Phase 3 gemtuzumab ozogamicin;Cytosine arabinoside;Daunomycin
24 High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia Completed NCT00002945 Phase 3 cyclophosphamide;cytarabine;etoposide;idarubicin;melphalan
25 Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia Completed NCT00046930 Phase 3 cytarabine;daunorubicin hydrochloride;zosuquidar trihydrochloride;Placebo
26 Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia Completed NCT00052299 Phase 3 cytarabine;etoposide;gemtuzumab ozogamicin;idarubicin;mitoxantrone hydrochloride
27 Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy Active, not recruiting NCT01307579 Phase 3 caspofungin acetate;fluconazole
28 Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Active, not recruiting NCT02085408 Phase 3 clofarabine;daunorubicin hydrochloride;cytarabine;decitabine
29 Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Active, not recruiting NCT00651261 Phase 3 cytarabine;daunorubicin;midostaurin;dexamethasone acetate
30 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
31 Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant Unknown status NCT02038153 Phase 1, Phase 2 Lenalidomide
32 Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia Unknown status NCT00003405 Phase 2 amifostine trihydrate;bromodeoxyuridine;cytarabine;idarubicin;idoxuridine;isotretinoin;mitoxantrone hydrochloride
33 Combination Chemotherapy in Treating Patients With Relapsed Acute Myelogenous Leukemia Unknown status NCT00003758 Phase 2 cytarabine;idarubicin
34 Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplasia Unknown status NCT00838240 Phase 1, Phase 2 clofarabine;cytarabine;idarubicin
35 VNP40101M Followed by Cytarabine in Treating Older Patients With Acute Myeloid Leukemia Unknown status NCT00354276 Phase 2 cytarabine;laromustine
36 Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Unknown status NCT00425477 Phase 2 bexarotene
37 Monoclonal Antibody in Treating Patients With Acute Myelogenous Leukemia Unknown status NCT00006084 Phase 2
38 Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia Completed NCT01870596 Phase 2 Cytarabine;CHK1 Inhibitor SCH 900776
39 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia Completed NCT01361464 Phase 2 Tipifarnib
40 High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma Completed NCT01177371 Phase 2 busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
41 Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia Completed NCT00666588 Phase 2 idarubicin;cytarabine;bortezomib;etoposide
42 Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia Completed NCT02144675 Phase 2 choline magnesium trisalicylate;idarubicin;cytarabine
43 Donor Stem Cell Transplant or Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia in Remission Completed NCT01020734 Phase 2 busulfan;cyclophosphamide;cyclosporine;fludarabine phosphate;methotrexate
44 Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT01349972 Phase 2 alvocidib;daunorubicin hydrochloride;mitoxantrone hydrochloride;cytarabine
45 AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed NCT01253447 Phase 2 Akt inhibitor MK2206
46 Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive Chemotherapy Completed NCT01235572 Phase 2
47 Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia Completed NCT00372619 Phase 1, Phase 2 clofarabine;cytarabine;methotrexate
48 Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML Completed NCT00895934 Phase 1, Phase 2 vorinostat;gemtuzumab ozogamicin;azacitidine
49 Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT00795002 Phase 2 alvocidib;mitoxantrone hydrochloride;cytarabine
50 Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Completed NCT00742625 Phase 1, Phase 2 daunorubicin hydrochloride;cytarabine;bortezomib

Search NIH Clinical Center for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22)

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils...

Genetic tests related to Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22):

# Genetic test Affiliating Genes
1 Acute Myelomonocytic Leukemia 29

Anatomical Context for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils...

MalaCards organs/tissues related to Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22):

41
Myeloid, Bone, Bone Marrow, Lung, Monocytes, Prostate, Skin

Publications for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils...

Articles related to Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22):

(show top 50) (show all 279)
# Title Authors Year
1
Human NUP98-IQCG fusion protein induces acute myelomonocytic leukemia in mice by dysregulating the Hox/Pbx3 pathway. ( 26675333 )
2016
2
Cardiopulmonary Failure Requiring ECMO Bypass Resulting from Leukemia Cell Lysis in a Patient with Childhood Acute Myelomonocytic Leukemia. ( 26124967 )
2015
3
A novel mutation of SETBP1 in atypical chronic myeloid leukemia transformed from acute myelomonocytic leukemia. ( 26185647 )
2015
4
MLL-ELL fusion gene in an acute myelomonocytic leukemia patient transformed from acute promyelocytic leukemia. ( 26185637 )
2015
5
Cochlear implantation in a patient with acute myelomonocytic leukemia before allogeneic peripheral blood stem cell transplantation. ( 24560096 )
2014
6
Targeted ex vivo reduction of CD64-positive monocytes in chronic myelomonocytic leukemia and acute myelomonocytic leukemia using human granzyme B-based cytolytic fusion proteins. ( 24523193 )
2014
7
A novel fusion of SQSTM1 and FGFR1 in a patient with acute myelomonocytic leukemia with t(5;8)(q35;p11) translocation. ( 25501022 )
2014
8
Bilateral Adrenal Masses in a Patient in Remission From Acute Myelomonocytic Leukemia. ( 24566206 )
2014
9
RANBP2-ALK fusion combined with monosomy 7 in acute myelomonocytic leukemia. ( 24613277 )
2014
10
Interaction Between Myelomonocytic and Lymphoid Cells in a Patient with Acute MyeloMonocytic Leukemia and Chronic Lymphocytic Leukemia. ( 23987820 )
2013
11
Interdigitating dendritic cell sarcoma presenting simultaneously with acute myelomonocytic leukemia: report of a rare case and literature review. ( 23605368 )
2013
12
Leukemic ascites as an initial presentation of acute myelomonocytic leukemia with inversion of chromosome 16. ( 23563011 )
2013
13
Thrombomodulin-induced differentiation of acute myelomonocytic leukemia cells via JNK signaling. ( 22342852 )
2012
14
Acute myelomonocytic leukemia presenting with gingival enlargement as the only clinical manifestation. ( 23493961 )
2012
15
Establishment and characterization of a new human acute myelomonocytic leukemia cell line JIH-3. ( 22340903 )
2012
16
p210 BCR/ABL1 as a secondary change in a patient with acute myelomonocytic leukemia (M4Eo) with inv(16). ( 23054652 )
2012
17
Myeloid Sarcoma and Acute Myelomonocytic Leukemia in an Adolescent with Tetrasomy 8: Staging with (18)F-FDG PET/CT. ( 24900045 )
2012
18
Acute myelomonocytic leukemia (AML-M4) in a dog with the extradural lesion. ( 21060242 )
2011
19
CD7-positive acute myelomonocytic leukemia with trisomy 21 as a sole acquired chromosomal abnormality in two adolescents. ( 21592571 )
2011
20
Double supernumerary isochromosome 4p in acute myelomonocytic leukemia. ( 20863564 )
2010
21
Isolated central nervous system relapse in an adolescent with acute myelomonocytic leukemia, Charcot Marie Tooth syndrome, and paraneoplastic autoantibody. ( 20724950 )
2010
22
Myeloid sarcoma in the nasal cavities that developed during the course of acute myelomonocytic leukemia. ( 21123976 )
2010
23
Pseudo Chediak-Higashi anomaly in acute myelomonocytic leukemia. ( 19332932 )
2009
24
Genome profiling of acute myelomonocytic leukemia: alteration of the MYB locus in MYST3-linked cases. ( 18818702 )
2009
25
Gemtuzumab ozogamicin-induced long-term remission in a woman with acute myelomonocytic leukemia and bone marrow relapse following allogeneic transplantation. ( 19904520 )
2009
26
Treatment-related acute myelomonocytic leukemia with t(11;19) in a child following chemotherapy for hepatoblastoma. ( 17973320 )
2008
27
A dog with acute myelomonocytic leukemia. ( 18628605 )
2008
28
Systemic mastocytosis with acute myelomonocytic leukemia: a case report. ( 23100960 )
2008
29
Comparative analysis of genes regulated in acute myelomonocytic leukemia with and without inv(16)(p13q22) using microarray techniques, real-time PCR, immunohistochemistry, and flow cytometry immunophenotyping. ( 17571080 )
2007
30
Mesenteric chloroma with t(16;16) followed by acute myelomonocytic leukemia with clonal evolution. ( 18036407 )
2007
31
Rare t(1;11)(q23;p15) in therapy-related myelodysplastic syndrome evolving into acute myelomonocytic leukemia: a case report and review of the literature. ( 17889707 )
2007
32
Parotid involvement in acute myelomonocytic leukemia. ( 17978464 )
2007
33
[Depressing the immune escape of acute myelomonocytic leukemia via an anti-Fas ribozyme]. ( 17096877 )
2006
34
Establishment of a stroma-dependent human acute myelomonocytic leukemia cell line, NAMO-2, with FLT3 tandem duplication. ( 17118759 )
2006
35
Dup(1)(p31.2p36.2) in acute myelomonocytic leukemia. ( 16490603 )
2006
36
Acute myelomonocytic leukemia in a boy with LEOPARD syndrome (PTPN11 gene mutation positive). ( 16679933 )
2006
37
Acute myelomonocytic leukemia with abnormal eosinophils: a case report with multi-modality diagnostic work-up. ( 17214400 )
2006
38
[Immunophenotypic and cytogenetic features of acute myelomonocytic leukemia]. ( 17059770 )
2006
39
Acute myelomonocytic leukemia with dysplastic bone marrow eosinophils showing t(5;17)(q13;q11) and a secondary chromosomal aberration, inv(16)(p13q22). ( 17189222 )
2006
40
Extra copy of 20q deletion, acute myelomonocytic leukemia (M4) and Niemann-Pick disease. ( 16027483 )
2005
41
Transient atypical monocytosis mimic acute myelomonocytic leukemia in post-chemotherapy patients receiving G-CSF: report of two cases. ( 15485468 )
2004
42
Erythema nodosum and granulomatous lesions preceding acute myelomonocytic leukemia. ( 15628321 )
2004
43
Deletion of CBFB in a patient with acute myelomonocytic leukemia (AML M4Eo) and inversion 16. ( 15381374 )
2004
44
Flow cytometry immunophenotypic characteristics of monocytic population in acute monocytic leukemia (AML-M5), acute myelomonocytic leukemia (AML-M4), and chronic myelomonocytic leukemia (CMML). ( 15603447 )
2004
45
[Study on the detection of inv(16) in acute myelomonocytic leukemia (M4) by flucorescence in situ hybridization method]. ( 15631653 )
2004
46
Childhood acute myelomonocytic leukemia (AML-M4) presenting as catastrophic antiphospholipid antibody syndrome. ( 15111789 )
2004
47
A pulmonary syndrome in patients with acute myelomonocytic leukemia and inversion of chromosome 16. ( 12691148 )
2003
48
A further case of acute myelomonocytic leukemia with inv(8) chromosomal rearrangement and MOZ-NCOA2 gene fusion. ( 12964013 )
2003
49
Oral manifestations of acute myelomonocytic leukemia: a case report and review of the classification of leukemias. ( 12083541 )
2002
50
Translocation (8;12)(q13;p13) during disease progression in acute myelomonocytic leukemia with t(11;19)(q23;p13.1). ( 12377416 )
2002

Variations for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils...

Expression for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils...

Search GEO for disease gene expression data for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22).

Pathways for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils...

Pathways related to Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22) according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.04 CREBBP CSF1 CSF1R KIT MYH11
2
Show member pathways
12.73 CREBBP CSF1 CSF1R FLT3 KIT
3
Show member pathways
12.7 CSF1R FLT3 KIT MYH11
4 12.6 CREBBP CSF1R FLT3 KIT RUNX1
5
Show member pathways
12.54 CREBBP CSF1R FLT3 KIT MPO RUNX1
6 12.53 CSF1 CSF1R FLT3 KIT
7
Show member pathways
12.48 CSF1 CSF1R FLT3 KIT
8 11.89 CSF1R FLT3 KIT
9 11.77 CSF1 FLT3 KIT MPO
10 11.45 CREBBP CSF1R KIT MPO
11 11.37 CSF1R ETV6 FLT3 KMT2A MPO RUNX1
12 11.34 CSF1 CSF1R DNTT FLT3 KIT
13 11.33 CSF1 CSF1R FLT3 KIT
14 11.31 CSF1 CSF1R KIT
15
Show member pathways
11.23 CREBBP CSF1 CSF1R
16 10.89 CREBBP ETV6 FLT3
17 10.73 CSF1 MPO
18 10.45 CBFB RUNX1

GO Terms for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils...

Cellular components related to Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22) according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 receptor complex GO:0043235 9.13 CSF1R FLT3 KIT
2 CSF1-CSF1R complex GO:1990682 8.62 CSF1 CSF1R

Biological processes related to Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22) according to GeneCards Suite gene sharing:

(show all 34)
# Name GO ID Score Top Affiliating Genes
1 transcription by RNA polymerase II GO:0006366 9.96 CBFB ETV6 KMT2A RUNX1
2 negative regulation of apoptotic process GO:0043066 9.96 CSF1R FLT3 KIT MPO
3 positive regulation of cell proliferation GO:0008284 9.94 CSF1 CSF1R FLT3 KIT
4 positive regulation of cell migration GO:0030335 9.83 CSF1 CSF1R KIT
5 protein autophosphorylation GO:0046777 9.8 CSF1R FLT3 KIT
6 cytokine-mediated signaling pathway GO:0019221 9.8 CSF1 CSF1R FLT3 KIT
7 peptidyl-tyrosine phosphorylation GO:0018108 9.79 CSF1R FLT3 KIT
8 positive regulation of MAPK cascade GO:0043410 9.78 CSF1R FLT3 KIT
9 negative regulation of signal transduction GO:0009968 9.72 CSF1R FLT3 KIT
10 regulation of hematopoietic stem cell differentiation GO:1902036 9.69 CBFB KMT2A RUNX1
11 regulation of Wnt signaling pathway GO:0030111 9.65 CBFB RUNX1
12 osteoclast differentiation GO:0030316 9.65 CSF1 CSF1R
13 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.63 FLT3 KIT
14 homeostasis of number of cells within a tissue GO:0048873 9.63 CSF1 KMT2A
15 positive regulation of kinase activity GO:0033674 9.61 CSF1R FLT3 KIT
16 macrophage differentiation GO:0030225 9.6 CSF1 CSF1R
17 definitive hemopoiesis GO:0060216 9.59 CBFB KMT2A
18 embryonic hemopoiesis GO:0035162 9.58 KIT KMT2A
19 regulation of intracellular estrogen receptor signaling pathway GO:0033146 9.58 CBFB RUNX1
20 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.58 CSF1R FLT3 KIT
21 regulation of keratinocyte differentiation GO:0045616 9.57 CBFB RUNX1
22 regulation of regulatory T cell differentiation GO:0045589 9.56 CBFB RUNX1
23 regulation of bicellular tight junction assembly GO:2000810 9.54 CBFB RUNX1
24 regulation of megakaryocyte differentiation GO:0045652 9.54 CBFB KMT2A RUNX1
25 hematopoietic stem cell proliferation GO:0071425 9.52 ETV6 RUNX1
26 regulation of B cell receptor signaling pathway GO:0050855 9.48 CBFB RUNX1
27 regulation of cytokine-mediated signaling pathway GO:0001959 9.46 CBFB RUNX1
28 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.46 CSF1 CSF1R FLT3 KIT
29 myeloid progenitor cell differentiation GO:0002318 9.32 FLT3 KIT
30 macrophage colony-stimulating factor signaling pathway GO:0038145 9.26 CSF1 CSF1R
31 regulation of myeloid cell differentiation GO:0045637 9.13 CBFB CREBBP RUNX1
32 hemopoiesis GO:0030097 9.02 CSF1 CSF1R FLT3 KIT RUNX1
33 positive regulation of transcription by RNA polymerase II GO:0045944 10.04 CBFB CREBBP ETV6 KMT2A RUNX1
34 cell differentiation GO:0030154 10.02 CSF1 CSF1R ETV6 FLT3 KIT

Molecular functions related to Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22) according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transferase activity GO:0016740 9.91 CREBBP CSF1R DNTT FLT3 KIT KMT2A
2 DNA binding transcription factor activity GO:0003700 9.85 CBFB CREBBP ETV6 KMT2A RUNX1
3 protein homodimerization activity GO:0042803 9.72 CSF1 CSF1R FLT3 KIT KMT2A
4 protein tyrosine kinase activity GO:0004713 9.58 CSF1R FLT3 KIT
5 MAP kinase kinase kinase activity GO:0004709 9.43 CSF1R FLT3 KIT
6 cytokine binding GO:0019955 9.37 CSF1R KIT
7 mitogen-activated protein kinase kinase binding GO:0031434 9.33 CSF1R FLT3 KIT
8 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.13 CSF1R FLT3 KIT
9 growth factor binding GO:0019838 8.8 CSF1R FLT3 KIT

Sources for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils...

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....